BR112013013369A8 - ligante sigma, uso do mesmo, método de tratamento de um paciente sofrendo dor de câncer ósseo ou propenso a sofrer dor como resultado de câncer ósseo e combinação de pelo menos um ligante sigma e pelo menos um composto opioide ou opiáceo - Google Patents

ligante sigma, uso do mesmo, método de tratamento de um paciente sofrendo dor de câncer ósseo ou propenso a sofrer dor como resultado de câncer ósseo e combinação de pelo menos um ligante sigma e pelo menos um composto opioide ou opiáceo

Info

Publication number
BR112013013369A8
BR112013013369A8 BR112013013369A BR112013013369A BR112013013369A8 BR 112013013369 A8 BR112013013369 A8 BR 112013013369A8 BR 112013013369 A BR112013013369 A BR 112013013369A BR 112013013369 A BR112013013369 A BR 112013013369A BR 112013013369 A8 BR112013013369 A8 BR 112013013369A8
Authority
BR
Brazil
Prior art keywords
pain
bone cancer
opioid
sigma ligand
prone
Prior art date
Application number
BR112013013369A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013013369A2 (pt
Inventor
Plata-Salaman Carlos
Zamanillo-Castanedo Daniel
Miguel Vela Hernández José
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of BR112013013369A2 publication Critical patent/BR112013013369A2/pt
Publication of BR112013013369A8 publication Critical patent/BR112013013369A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112013013369A 2010-12-03 2011-12-02 ligante sigma, uso do mesmo, método de tratamento de um paciente sofrendo dor de câncer ósseo ou propenso a sofrer dor como resultado de câncer ósseo e combinação de pelo menos um ligante sigma e pelo menos um composto opioide ou opiáceo BR112013013369A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382330A EP2460519A1 (en) 2010-12-03 2010-12-03 Use of sigma ligands in bone cancer pain
PCT/EP2011/071584 WO2012072782A1 (en) 2010-12-03 2011-12-02 Use of sigma ligands in bone cancer pain

Publications (2)

Publication Number Publication Date
BR112013013369A2 BR112013013369A2 (pt) 2016-09-06
BR112013013369A8 true BR112013013369A8 (pt) 2018-01-09

Family

ID=43629676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013369A BR112013013369A8 (pt) 2010-12-03 2011-12-02 ligante sigma, uso do mesmo, método de tratamento de um paciente sofrendo dor de câncer ósseo ou propenso a sofrer dor como resultado de câncer ósseo e combinação de pelo menos um ligante sigma e pelo menos um composto opioide ou opiáceo

Country Status (35)

Country Link
US (1) US20130324535A1 (enExample)
EP (2) EP2460519A1 (enExample)
JP (1) JP6027014B2 (enExample)
KR (1) KR101855358B1 (enExample)
CN (1) CN103313709B (enExample)
AR (1) AR084730A1 (enExample)
BR (1) BR112013013369A8 (enExample)
CA (1) CA2819442C (enExample)
CO (1) CO6781549A2 (enExample)
CY (1) CY1119030T1 (enExample)
DK (1) DK2646025T3 (enExample)
ES (1) ES2626672T3 (enExample)
HR (1) HRP20170818T1 (enExample)
HU (1) HUE033488T2 (enExample)
IL (1) IL226706A (enExample)
LT (1) LT2646025T (enExample)
MA (1) MA34878B1 (enExample)
ME (1) ME02852B (enExample)
MX (1) MX343773B (enExample)
MY (1) MY171994A (enExample)
NZ (1) NZ612119A (enExample)
PH (1) PH12013501127A1 (enExample)
PL (1) PL2646025T3 (enExample)
PT (1) PT2646025T (enExample)
RS (1) RS56081B1 (enExample)
RU (1) RU2585095C2 (enExample)
SG (1) SG190745A1 (enExample)
SI (1) SI2646025T1 (enExample)
SM (1) SMT201700270T1 (enExample)
TN (1) TN2013000227A1 (enExample)
TR (1) TR201708567T4 (enExample)
TW (1) TWI629060B (enExample)
UA (1) UA112638C2 (enExample)
WO (1) WO2012072782A1 (enExample)
ZA (1) ZA201304966B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
EP3043795A1 (en) * 2013-09-12 2016-07-20 Laboratorios Del. Dr. Esteve, S.A. Nsaid and sigma receptor ligand combinations
JP2017503765A (ja) 2013-12-17 2017-02-02 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ガバペンチノイドおよびシグマ受容体の組み合わせ
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
EP2929883A1 (en) * 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
WO2018011169A1 (en) * 2016-07-12 2018-01-18 Laboratorios Del Dr. Esteve, S.A. Use of sigma receptor ligands in post-herpetic pain
EP3415143A1 (en) * 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine for the treatment of pain
CN112165955A (zh) * 2018-05-21 2021-01-01 益普生生物制药有限公司 抑制骨癌引起的异常性疼痛
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
KR102744822B1 (ko) 2020-06-05 2024-12-20 주식회사 허밍아비스 발열체 조성물 및 이를 이용한 마스크 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2298743T3 (pl) * 2003-06-26 2013-02-28 Novartis Ag Inhibitory kinaz P38 na bazie 5-członowych heterocykli
PL1781618T3 (pl) * 2004-08-27 2013-03-29 Esteve Labor Dr Inhibitory receptora sigma
DK1781618T3 (da) * 2004-08-27 2012-10-29 Esteve Labor Dr Sigma-receptorinhibitorer
MX2008011016A (es) * 2006-03-01 2008-09-08 Esteve Labor Dr Inhibidores de receptor sigma.
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

Also Published As

Publication number Publication date
EP2646025A1 (en) 2013-10-09
ES2626672T3 (es) 2017-07-25
EP2646025B1 (en) 2017-03-15
TW201249805A (en) 2012-12-16
LT2646025T (lt) 2017-06-12
SMT201700270T1 (it) 2017-07-18
WO2012072782A1 (en) 2012-06-07
US20130324535A1 (en) 2013-12-05
EP2460519A1 (en) 2012-06-06
CO6781549A2 (es) 2013-10-31
AU2011334880A1 (en) 2013-07-11
HRP20170818T1 (hr) 2017-08-25
JP6027014B2 (ja) 2016-11-16
TR201708567T4 (tr) 2019-01-21
CA2819442C (en) 2018-06-12
PT2646025T (pt) 2017-06-26
SI2646025T1 (sl) 2017-07-31
ME02852B (me) 2018-04-20
IL226706A (en) 2015-07-30
CN103313709A (zh) 2013-09-18
MY171994A (en) 2019-11-11
NZ612119A (en) 2014-06-27
RU2013130222A (ru) 2015-01-10
JP2014501732A (ja) 2014-01-23
SG190745A1 (en) 2013-07-31
RS56081B1 (sr) 2017-10-31
AU2011334880B2 (en) 2016-09-15
ZA201304966B (en) 2014-09-25
BR112013013369A2 (pt) 2016-09-06
HUE033488T2 (en) 2017-12-28
MA34878B1 (fr) 2014-02-01
MX343773B (es) 2016-11-23
DK2646025T3 (en) 2017-06-06
CN103313709B (zh) 2017-05-24
CY1119030T1 (el) 2018-01-10
AR084730A1 (es) 2013-06-05
PL2646025T3 (pl) 2017-09-29
CA2819442A1 (en) 2012-06-07
UA112638C2 (uk) 2016-10-10
MX2013006140A (es) 2013-07-03
KR20130135881A (ko) 2013-12-11
KR101855358B1 (ko) 2018-05-04
TWI629060B (zh) 2018-07-11
RU2585095C2 (ru) 2016-05-27
PH12013501127A1 (en) 2020-10-19
TN2013000227A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
BR112013013369A8 (pt) ligante sigma, uso do mesmo, método de tratamento de um paciente sofrendo dor de câncer ósseo ou propenso a sofrer dor como resultado de câncer ósseo e combinação de pelo menos um ligante sigma e pelo menos um composto opioide ou opiáceo
IL295704B1 (en) Equipment and methods for tissue microbibilization using fractional treatment patterns
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
WO2012062925A3 (en) Compounds and methods for treating pain
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112013014583A2 (pt) composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila
EA201290919A1 (ru) Индазольные соединения и их применение
BR112013002167A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
EP2621588A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASE USING INHALATION
ZA201300218B (en) Treatment of blood cancer
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
PL2589579T3 (pl) Zastosowanie zestawu do obróbki powierzchni zaszpachlowanych gipsem, zatartych gipsem lub otynkowanych gipsem
BR112013001297A2 (pt) composições farmacêuticas e respectivo uso e método de tratamento de doença ou condição respiratória
IL229495B (en) A sigma receptor ligand for the treatment of pain resulting from type ii diabetes
BR112015000649A2 (pt) compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção
BR112015012877A2 (pt) composto de fórmula, composição farmacêutica, uso do composto e método para o tratamento do câncer
FI20115078A7 (fi) Maanpeitekate, katteen käsittelyaine ja menetelmä maanpeitekatteen valmistamiseksi ja katteen ja käsittelyaineen käyttö
BR112015003201A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar ou melhorar o cãncer
BRPI0923688A2 (pt) compostos e métodos para o tratamento de dor e outras doenças
WO2013188750A3 (en) Substituted macrocyclic compounds having proteasome inhibitory activity
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
EP2593111A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
BR112013017184A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças
WO2012018866A3 (en) Methods and compositions for the diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements